The BIOVEA project

// Project

The BIOVEA project

Duration of the project

42 months

Financing contract


Submission code



"Nicolae Simionescu" Institute of Cellular Biology and Pathology
National Research-Development Institute in the Field of Pathology and Biomedical Sciences "Victor
Babeș" Bucharest
"Carol Davila" University of Medicine and Pharmacy Bucharest
OncoGen-Pius Brânzeu Emergency County Clinical Hospital, Timișoara

Project details

Development of BIOnanotechnologies based on Extracellular Vesicles, applicable in the early diagnosis, prognosis and therapy of Atherosclerotic disease (BIOVEA) – 83PCCDI/2018

Funding: 5,287,500.00 lei RON 

Coordinator: "Nicolae Simionescu" Institute of Cellular Biology and Pathology 

Specific objectives:

  • the identification of circulating extracellular vesicles, as biomarkers for experimental coronary atherosclerotic disease;
  • validation of circulating extracellular vesicles as biomarkers for early diagnosis and establishing the prognosis of stable coronary disease in humans;
  • establishing an optimal cellular source for the "in vitro" generation of extracellular vesicles, with therapeutic potential in coronary atherosclerotic disease;
  • exploring the therapeutic potential of extracellular vesicles in experimental models of cardiac hypertrophy and coronary atherosclerosis.

The introduction of these new investigation models (in vitro and in vivo), transferable methods and technologies in clinical practice, used for diagnosis and treatment, will have direct implications on the health status of the population.



Obtaining mesenchymal stem cells from bone marrow and adipose tissue to define the optimal source of exosomes and microparticles.

Characterization of VECs obtained in culture and definition of the optimal source of exosomes and microparticles for applications in atherosclerotic disease.

New or significantly improved technologies made and transferred to the economy:
1. Procedure for obtaining genetically modified (encapsulated) extracellular vesicles;
2. "In vivo" procedure for tracking VEC biodistribution;
3. "In vivo" methods for validating VEC as therapeutic strategies.

Fig. 1. Obtaining ADSC (adipose-derived stem cells) and BM-MSC (bone marrow-derived mesenchymal stem cells) from wild-type hamsters